For more than a decade, the International Myeloma Foundation has attended the American Society of Hematology (ASH) annual meeting, an exciting convergence of thousands of healthcare professionals from around the world. Explore this page to learn about the latest blood cancer research from the meeting, especially key clinical trials to advance the treatment and management of multiple myeloma.
IMF Chairman Emeritus and Chief Scientific Officer Dr. Brian G.M. Durie gives an overview of what’s to come during this year’s 65th ASH Annual Meeting and Exposition. With more than 7,000 accepted abstracts “representing the most cutting-edge science in hematology,” myeloma scientific content for this year’s ASH will be jampacked in sessions spanning three days. For sessions with overlapping schedules, Dr. Durie advises to use the “teamwork approach” to cover as many abstracts as possible. He makes mention of 2023’s “hot topics”—real-world data, drug access, and racial disparities—and how they will play a major part during this year’s ASH.
Tune in as the IMF brings myeloma support group leaders and patients to the 65th annual meeting of the American Society of Hematology (ASH), “the world’s most comprehensive hematology event of the year.” The IMF thanks these leaders for their care and commitment in sharing their experiences with the global myeloma community. We encourage you to visit the website and follow these leaders for their unique perspectives.
Every year at ASH, the IMF films dozens of videos with leading myeloma experts and other Key Opinion Leaders at the American Society of Hematology Annual Meeting & Exposition. This year promises 25+ upcoming videos on some of the most-discussed myeloma-related abstracts from ASH 2023. Click the Learn More button below to explore now.
The International Myeloma Foundation’s Black Swan Research Initiative® (BSRI) proudly showcased four oral and two poster abstracts from the iStopMM (Iceland Screens, Treats, or Prevents Multiple Myeloma) Project during the 65th American Society of Hematology (ASH) Annual Meeting in San Diego. Also, StopMM team members Thorir Einarsson Long, Jon Thorir Oskarsson, and Sæmundur Rognvaldsson are 2023 ASH Abstract Achievement Awardees. Read the full press release to learn more.
Semaje Testamark, an IMF Medical Student Scholar, stands among the recipients of the prestigious 2023 ASH Abstract Achievement Award, marking a significant achievement in health equity research. Collaborating with Dr. Manisha Bhutani of Atrium Health Levine Cancer Institute, Testamark's study on "Rural-Urban and Racial Trends in Survival of Patients with Multiple Myeloma" sheds light on disparities in healthcare access. Testamark's recognition underscores the IMF's commitment to nurturing diverse talent and fostering health equity research. LEARN MORE.
Watch the Replay of this IMWG Conference Series, “Making Sense of Treatment.” Leading myeloma experts discussed the latest myeloma research news from the 2023 American Society of Hematology (ASH) Annual Meeting and Expo.
IMF Chief Scientific Officer Dr. Brian G.M. Durie moderated the discussion, with Drs. María V. Mateos (University of Salamanca—Salamanca, Spain) and Thomas Martin (University of California San Francisco—San Francisco, CA) serving as panelists. WATCH NOW.
IMF Chief Medical Officer Dr. Joseph Mikhael along with the ASH support group leader team go live to discuss key myeloma research takeaways from the 2023 American Society of Hematology meeting and exposition. This Facebook Live Event took place on Monday, December 11, at 7:00 p.m. PST / 10:00 p.m. EST. Visit the Facebook event page to view now. WATCH NOW.
IMF Chief Scientific Officer Brian G.M. Durie discusses important Top Myeloma Research and Key Takeaways from the 2023 American Society of Hematology (ASH) Conference, along with a panel of patient advocates including Jessie Daw, PhD, and Michael Tuohy. Together, they sift through the data of 1,000+ myeloma-related abstracts from the ASH conference and present key points in approachable terms for everyday decision-making. WATCH NOW.
